
==== Front
Crit Care
Critical Care
1364-8535
1466-609X
BioMed Central London

5083
10.1186/s13054-024-05083-y
Research
Cerebral physiologic insult burden in acute traumatic neural injury: a Canadian High Resolution-TBI (CAHR-TBI) descriptive analysis
Stein Kevin Y. steink34@myumanitoba.ca

12
Gomez Alwyn 34
Griesdale Donald 5
Sekhon Mypinder 56
Bernard Francis 7
Gallagher Clare 8910
Thelin Eric P. 1112
Raj Rahul 13
Aries Marcel 14
Froese Logan 1112
Kramer Andreas 91015
Zeiler Frederick A. 141216
1 https://ror.org/02gfys938 grid.21613.37 0000 0004 1936 9609 Department of Biomedical Engineering, Price Faculty of Engineering, University of Manitoba, Winnipeg, MB Canada
2 https://ror.org/02gfys938 grid.21613.37 0000 0004 1936 9609 Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB Canada
3 https://ror.org/02gfys938 grid.21613.37 0000 0004 1936 9609 Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB Canada
4 https://ror.org/02gfys938 grid.21613.37 0000 0004 1936 9609 Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB Canada
5 https://ror.org/03rmrcq20 grid.17091.3e 0000 0001 2288 9830 Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, BC Canada
6 https://ror.org/03rmrcq20 grid.17091.3e 0000 0001 2288 9830 Division of Critical Care, Department of Medicine, University of British Columbia, Vancouver, BC Canada
7 https://ror.org/0161xgx34 grid.14848.31 0000 0001 2104 2136 Section of Critical Care, Department of Medicine, University of Montreal, Montreal, QC Canada
8 https://ror.org/03yjb2x39 grid.22072.35 0000 0004 1936 7697 Section of Neurosurgery, University of Calgary, Calgary, AB Canada
9 https://ror.org/03yjb2x39 grid.22072.35 0000 0004 1936 7697 Department of Clinical Neurosciences, University of Calgary, Calgary, AB Canada
10 https://ror.org/03yjb2x39 grid.22072.35 0000 0004 1936 7697 Hotchkiss Brain Institute, University of Calgary, Calgary, AB Canada
11 https://ror.org/00m8d6786 grid.24381.3c 0000 0000 9241 5705 Medical Unit Neurology, Karolinska University Hospital, Stockholm, Sweden
12 https://ror.org/056d84691 grid.4714.6 0000 0004 1937 0626 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
13 grid.7737.4 0000 0004 0410 2071 Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
14 https://ror.org/02jz4aj89 grid.5012.6 0000 0001 0481 6099 Department of Intensive Care, Maastricht University Medical Center+ and School of Mental Health and Neurosciences, University Maastricht, Maastricht, The Netherlands
15 https://ror.org/03yjb2x39 grid.22072.35 0000 0004 1936 7697 Department of Critical Care Medicine, University of Calgary, Calgary, AB Canada
16 grid.490345.f 0000 0004 0467 0538 Pan Am Clinic Foundation, Winnipeg, MB Canada
4 9 2024
4 9 2024
2024
28 2949 7 2024
29 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Over the recent decades, continuous multi-modal monitoring of cerebral physiology has gained increasing interest for its potential to help minimize secondary brain injury following moderate-to-severe acute traumatic neural injury (also termed traumatic brain injury; TBI). Despite this heightened interest, there has yet to be a comprehensive evaluation of the effects of derangements in multimodal cerebral physiology on global cerebral physiologic insult burden. In this study, we offer a multi-center descriptive analysis of the associations between deranged cerebral physiology and cerebral physiologic insult burden.

Methods

Using data from the Canadian High-Resolution TBI (CAHR-TBI) Research Collaborative, a total of 369 complete patient datasets were acquired for the purposes of this study. For various cerebral physiologic metrics, patients were trichotomized into low, intermediate, and high cohorts based on mean values. Jonckheere–Terpstra testing was then used to assess for directional relationships between these cerebral physiologic metrics and various measures of cerebral physiologic insult burden. Contour plots were then created to illustrate the impact of preserved vs impaired cerebrovascular reactivity on these relationships.

Results

It was found that elevated intracranial pressure (ICP) was associated with more time spent with cerebral perfusion pressure (CPP) < 60 mmHg and more time with impaired cerebrovascular reactivity. Low CPP was associated with more time spent with ICP > 20 or 22 mmHg and more time spent with impaired cerebrovascular reactivity. Elevated cerebrovascular reactivity indices were associated with more time spent with CPP < 60 mmHg as well as ICP > 20 or 22 mmHg. Low brain tissue oxygenation (PbtO2) only demonstrated a significant association with more time spent with CPP < 60 mmHg. Low regional oxygen saturation (rSO2) failed to produce a statistically significant association with any particular measure of cerebral physiologic insult burden.

Conclusions

Mean ICP, CPP and, cerebrovascular reactivity values demonstrate statistically significant associations with global cerebral physiologic insult burden; however, it is uncertain whether measures of oxygen delivery provide any significant insight into such insult burden.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13054-024-05083-y.

Keywords

Traumatic brain injury
Cerebral physiologic insult burden
Multi-modal monitoring
Cerebral physiology
http://dx.doi.org/10.13039/501100000038 Natural Sciences and Engineering Research Council of Canada CGS D-579021-2023 ALLRP-576386-22 Stein Kevin Y. Zeiler Frederick A. University of Manitoba Endowed Manitoba Public Insurance (MPI) Chair in Neuroscienceissue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

The pathophysiology underlying traumatic brain injury (TBI) can generally be divided into two distinct phases: primary and secondary brain injury. Primary injury refers to the immediate disruptions in brain structure, such as contusions, hemorrhages, or diffuse axonal injuries, that occur as a direct result of the mechanical forces involved in the traumatic incident [1, 2]. Secondary brain injury encompasses the downstream systemic and cellular derangements, driven mainly by host responses to the primary injury, which result in ongoing neuronal death and delayed recovery [2, 3]. Since little can be done to reverse primary brain injury, moderate-to-severe TBI management is primarily focused on limiting secondary injury.

Intracranial hypertension and cerebral ischemia are two significant contributors to secondary brain injury and have been found to be strongly associated with poor outcomes [4–9]. Therefore, intracranial pressure (ICP) and cerebral perfusion pressure (CPP) have become key targets for therapeutic intervention in the management of moderate-to-severe TBI. Invasive ICP and arterial blood pressure (ABP) monitoring allow for the continuous monitoring of these parameters, CPP = ABP–ICP, and guide clinical management in this patient cohort. Current established management guidelines recommend maintaining ICP below a threshold of 20 or 22 mmHg and CPP between 60 and 70 mmHg [10, 11]. However, despite significant advances in our ability to achieve these targets over the past few decades, there has been limited improvement in the outcomes associated with moderate-to-severe TBI [2, 12, 13].

As a result, there has been increasing interest in the integration of additional continuous cerebral physiologic monitoring modalities to help further minimize secondary injury following TBI and improve outcomes. Due to their high metabolic demand and limited energy stores, cerebral tissues are highly sensitive to ischemia, with a mere five minutes of obstructed blood flow being able to result in irreversible damage [14]. Therefore, a handful of monitoring modalities that provide insight into the adequacy of cerebral perfusion and nutrient delivery have been considered for their potential to augment current clinical management. These include cerebrovascular reactivity, brain tissue oxygenation (PbtO2), and near-infrared spectroscopy (NIRS) monitoring.

Despite the increasing interest in multimodal cerebral physiologic monitoring, there is yet to be a comprehensive evaluation of the effects of derangements in continuous multimodal cerebral physiologic parameters on measures of cerebral physiologic insult burden. We, therefore, offer a multicenter descriptive analysis of the associations between derangements in continuous multimodal cerebral physiology and cerebral physiologic insult burden. Additionally, as a secondary aim, we hope to illustrate the protective effects that preserved cerebrovascular reactivity has on such relationships.

Methods

Study design

For the purposes of this retrospective descriptive analysis, we accessed prospectively collected datasets from the Canadian High Resolution-TBI (CAHR-TBI) Research Collaborative [15]. As part of this ongoing multicenter research collaborative, high-resolution physiologic data was collected from all adult (≥ 18 years) moderate-to-severe TBI patients admitted to the intensive care unit (ICU), for invasive physiologic monitoring, at one of four university-affiliated hospitals: Foothills Medical Centre (University of Calgary), Health Sciences Centre Winnipeg (University of Manitoba), Maastricht University Medical Center + (University of Maastricht), and Vancouver General Hospital (University of British Columbia).

Patients were included in this database if all of the following were satisfied: patient was admitted to the ICU of one of the member hospitals, patient was deemed to have suffered a moderate-to-severe TBI (as defined as having a Glasgow Coma Scale [GCS] of less than 13), patient had both invasive ICP and ABP monitoring available, patient was at least 18 years of age, initiation of data collection was possible within 24 h of the initial traumatic incident. Patients were excluded if any of these conditions were not satisfied, or if the patient had a cerebral shunt in place (as this would prevent observation of a proper ICP waveform).

In addition to high-resolution physiology data, demographics information (i.e. age, sex), admission characteristics (i.e. admission GCS, pupillary reactivity), imaging results (i.e. Marshall Computed Tomography score), and clinical outcome scoring (Glasgow Outcome Scale [GOS]) were also collected. All data collection occurred in an entirely de-identified fashion. Data entry spanned from 2011 to 2021 for the University of Calgary, 2019–2023 for the University of Manitoba, 2017–2022 for the University of Maastricht, and 2014–2019 for the University of British Columbia.

Ethics

Ethics approval in regard to all aspects of data collection and anonymous data transfer between centers for this database has been granted by each site’s local research ethics board: University of Manitoba Biomedical Research Ethics Board (BREB, H2017:181, H2017:188, B2018:103, B2019:065, H2020:118, B2023:001), University of Calgary Conjoint Health Research Ethics Board (CHREB, H20-03759), University of British Columbia Clinical Research Ethics Board (CREB, REB20-0482) and University of Maastricht Medical Ethics Committee (16-4-243). As data collection is entirely anonymized, the respective research ethics boards have granted approval for data collection to operate under a waived consent model.

Patient population

For our analysis, we retrospectively accessed all available archived datasets from the CAHR-TBI Research Collaborative. All patients had suffered a moderate-to-severe TBI, defined as having an admission Glasgow Coma Scale (GCS) of less than 13. Patients received standard care in accordance with Brain Trauma Foundation (BTF) guidelines, which recommends invasive monitoring of ICP and ABP, as well as therapeutic maintenance of ICP below 20–22 mmHg and CPP above 60 mmHg [10, 11]. It should be noted that hyperemic CPP was not typically treated as per local practice. Additionally, neither cerebrovascular reactivity monitoring nor NIRS-based rSO2 are part of any existing institutional clinical algorithms at any of the participating centers. However, it should be noted that these values are visible on patient bedside data collection carts and, therefore, could theoretically have been considered by treating clinicians during their clinical decision making.

At all participating hospitals, no established guideline on when PbtO2 monitoring should be utilized exists. Therefore, insertion of a Licox probe for monitoring PbtO2 is entirely at the discretion of the treating physician. Further, there is no established consensus among the participating centers on how PbtO2 should be used in guiding management, with local practice norms varying drastically between centers, from aggressive management to solely observational. However, the Brain Trauma Foundation guidelines do suggest maintenance of PbtO2 above 20 mmHg [11]. Physiologic data recordings were initiated within 24 h from the time of injury and following placement of invasive monitoring devices and admission into the ICU. Data collection continued until invasive physiologic monitoring was discontinued by the treating physician. At 6-month follow-up appointments, patients had their long-term outcomes evaluated and recorded using GOS.

Physiologic data collection

ICP was continuously monitored using an intraparenchymal strain gauge probe (Codman ICP MicroSensor, Codman & Shurtlef Inc., Raynham, MA, USA; NEUROVENT-TEMP, RAUMEDIC, Helmbrechts, Germany) placed in the patient’s frontal lobe, or an external ventricular drain (EVD; Medtronic, Minneapolis, MN). No corrections were made for any zero drift of monitors. Continuous monitoring of ABP was performed using a radial or femoral line connected to a pressure transducer (Baxter Healthcare Corp. CardioVascular Group, Irvine, CA, USA; Edwards, Irvine, CA, USA), zeroed at the level of the tragus [16, 17].

rSO2 was recorded using NIRS regional oximetry of the left and right frontal lobes (INVOS 5100C or 7100, Covidien-Medtronic, Minneapolis, MN), whenever possible. At the discretion of the treating clinician, PbtO2 was monitored using an intra-parenchymal brain tissue oxygenation probe (Licox Brain Tissue Oxygen Monitoring System; Integra LifeSciences Corp., Plainsboro, New Jersey), placed in the frontal lobe. All available high-frequency full wave-form physiology was then recorded in digital time-series from the patients’ bedside ICU monitors using Intensive Care Monitoring “Plus” software (ICM+) (Cambridge Enterprise Ltd, Cambridge, UK, http://icmplus.neurosurg.cam.ac.uk) using either direct digital data transfer or analog-to-digital signal conversion (DT9804/DT9826, Data Translations, Marlboro, MA, USA).

Data processing

All post-acquisition signal processing was performed using ICM+ software. To ensure quality of raw data, signal artifacts were removed by qualified personnel without knowledge of the study objectives or patient demographics. This involved removing segments of data that lacked proper waveform morphology or had implausibly high/low values. For any cases where ICP was monitored using an EVD, drain opening artifacts were addressed via manual curation. For each patient who received NIRS monitoring, a single rSO2 signal was obtained. The NIRS channel/side used was chosen based on radiographic information, when available, in order to avoid signal interference from hematomas or contusions underlying the sensors. In cases where both channels had such underlying injuries, neither channel was used. When both channels were viable, the signals were averaged to obtain a single rSO2 signal.

Following artifact clearing, pulse amplitude of ICP (AMP) was calculated by conducting Fourier analysis of the fundamental amplitude of the ICP pulse waveform over sequential 10-s windows of data [18, 19]. A 10-s non-overlapping moving average filter was applied to down-sample ICP, ABP (producing mean arterial pressure [MAP]), and AMP, in order to focus on the frequency range associated with cerebral vasomotion and minimize the effects of the respiratory cycle [13, 20, 21]. Then, CPP was calculated by subtracting ICP from MAP; CPP = MAP–ICP.

Three ICP-based cerebrovascular reactivity indices were derived: the pressure reactivity index (PRx—correlation between ICP and MAP), the pulse amplitude index (PAx—correlation between AMP and MAP), and RAC (the correlation (R) between AMP (A) and CPP (C)) [18, 22, 23]. These metrics were calculated as the Pearson correlations of 300-s windows of ICP and MAP (for PRx), AMP and MAP (for PAx), and AMP and CPP (for RAC), continuously updating every minute [22–26]. Two NIRS-based cerebrovascular reactivity indices were also derived in a similar manner, in accordance with the convention of recent literature: COx (correlation between rSO2 and CPP) and COx_a (correlation between rSO2 and ABP) [27–30]. Additionally, RAP (the correlation (R) between AMP (A) and ICP (P)) was calculated as a representative metric for cerebral compliance [19, 31]. Finally, all data was down-sampled to minute-by-minute resolution and output as a comma-separated values (CSV) file for each individual patient before further processing in R Statistical Computing software (R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/).

Data analysis

All statistical tests employed in this study were chosen prior to running any analyses. R Statistical Computing software was used to conduct all data analysis. The following add-on R packages were leveraged for the purposes of this analysis: purr, dplyr, ggplot2, plotly, reticulate, and clinfun. First, mean values of all physiologic metrics were computed for each patient over their entire recording period. Next, time spent with various cerebral physiologic metrics, with known associations with patient outcomes, above/below literature defined thresholds were calculated to represent cerebral physiologic insult burden. The thresholds that were used can be found in Supplemental Appendix A.

A summary of the cerebral physiologic insult burden and demographics of the entire patient cohort was then created using medians and interquartile ranges (IQR), or raw counts, where appropriate. Patients were then dichotomized based on 6-month outcome into the following: Alive (GOS > 1) versus Dead (GOS = 1) and Favorable (GOS > 3) versus Unfavorable (GOS ≤ 3) [32]. Physiologic and demographic differences between these outcome cohorts were then evaluated using Mann–Whitney U and Chi-square testing, for continuous and non-continuous variables, respectively. Next, patients were trichotomized based on mean values for each of the multimodal cerebral physiologic parameters of interest: ICP, CPP, PRx, PAx, RAC, PbtO2, and rSO2. For each patient, the mean values used for trichotomization were calculated by taking the average of all minute-by-minute data points of the parameter of interest across the patient’s entire recording period. The trichotomization groupings can be found in Supplemental Appendix B.

Jonckheere–Terpstra testing was then used to evaluate whether a directional relationship exists between these parameters and various measures of cerebral physiologic insult burden. Histograms were also created to illustrate the spread in insult burden metrics between the groupings of each trichotomization. Stacked bar plots were also produced to compare the distribution of % time spent with cerebral physiologic metrics in various ranges between the trichotomized groupings. Finally, contour plots were produced to demonstrate the effects that cerebrovascular reactivity has on the relationships between multimodal cerebral physiologic parameters and the insult burden metrics. Data points outside of two standard deviations from the mean value of each axis were excluded during the generation of these plots. This was done to reduce the area of the plots that needed to be interpolated. Data points used to produce these plots were overlayed to allow for visual inspection of the distribution of the data. Alpha was set to 0.05 for all statistical tests. Unadjusted p-values will be presented throughout the text; however, p-values corrected for multiple comparisons using the false discovery rate (FDR) method will also be presented in the tables [33–35].

Results

Patient population

A total of 369 patient datasets from the CAHR-TBI research collaborative were included in this analysis (120 originating from the University of Calgary, 125 from the University of Manitoba, 51 from the University of Maastricht, and 77 from the University of British Columbia). All patients had their ICP and ABP invasively monitored; however, only 146 (40%) and 116 (31%) patients had their rSO2 and PbtO2 monitored, respectively. The median age of this cohort was 38 years (IQR = 24–55) with approximately 78% of patients being male. All patients suffered a moderate-to-severe TBI, with a median admission GCS of 6 (IQR = 3–7). This cohort exhibited a 6-month mortality rate of 36%, with 77% of those who survived having a favorable outcome. A complete summary of the cerebral physiology and demographics of this patient cohort can be found in Supplemental Appendix C.

The results of the Mann–Whitney U/Chi-square testing comparing the Alive versus Dead and Favorable versus Unfavorable groupings can be found in Supplemental Appendix D. Older age, lower admission GCS, greater Marshal computerized tomography grade, greater mean values and time spent above thresholds of ICP and ICP-based cerebrovascular reactivity indices, lower mean CPP, and less time spent with CPP above 70 mmHg were seen in the non-survivors. Similarly, for the Unfavorable group, older age, lower admission GCS, and greater mean values and time spent above thresholds of ICP and ICP-based cerebrovascular reactivity indices were observed.

ICP

Upon Jonckheere–Terpstra testing for ICP trichotomization, it was found that increasing ICP had a directional relationship with greater values in the following cerebral physiologic insult burden metrics: % time spent with CPP < 60 mmHg (p = 0.002), % time spent with PRx above its literature defined thresholds (p values range between 0.014 and 0.018), % time with PAx above its thresholds (p values range between 0.010 and 0.022), and % time spent with RAP > 0.4 (p = 0.036). Neither % time with RAC > 0 nor time spent above either of the NIRS-based cerebrovascular reactivity indices were able to demonstrate such an association. Interestingly, % time with CPP > 70 mmHg was found to be greater at lower ICP levels (p = 0.048). These findings can be found in Table 1.Table 1 Jonckheere–Terpstra Testing for ICP Trichotomization

Variable	ICP < 20 mmHg
(n = 337)	20 mmHg ≤ ICP ≤ 25 mmHg
(n = 26)	ICP > 25 mmHg
(n = 10)	J–T statistic	p-value	Adjusted p-value	
Age (years)	39 (24.2–55)	33.5 (25–55)	27 (19–39.8)	5518	0.306	0.453	
Sex (% male)	78.87%	61.54%	90%	5645	0.290	0.446	
Admission GCS	6 (4–7)	6 (3–7)	3 (3–3.25)	3764	0.100	0.191	
Admission GCS—motor	4 (1–5)	4 (1–5)	1 (1–1.75)	2779	0.466	0.583	
Admission pupil response (% bilaterally reactive)	15.90%	3.85%	30%	6190	0.736	0.818	
Marshall CT grade	3 (2–5)	3 (2–3)	4 (3.25–4)	5835	0.930	0.930	
GOS	4 (1–5)	1 (1–2.5)	1 (1–1)	2879	0.002	0.009	
Number with hypoxic episode	26.50%	35.29%	50%	2649	0.178	0.297	
Number with hypotensive episode	15.08%	18.75%	33.33%	2412	0.344	0.469	
Duration of recording (hours)	98.4 (53.4–186)	123 (83.2–197)	23.5 (16.6–69.5)	5600	0.322	0.460	
Mean MAP (mmHg)	86.9 (81.1–92.9)	97 (90.2–102)	91.2 (87.3–97.3)	9192	0.002	0.009	
Mean ICP (mmHg)	11.9 (8.17–14.8)	21.2 (20.7–22.8)	33.4 (29.7–50.6)	12,392	0.002	0.009	
% Time ICP > 20 mmHg	3.81 (0.485–13.9)	56.8 (49.7–62.6)	82.8 (78.5–94)	12,330	0.002	0.009	
% Time ICP > 22 mmHg	2.11 (0.229–7.69)	43.3 (35–50.3)	75.9 (71.5–91.7)	12,288	0.002	0.009	
Mean CPP (mmHg)	74.9 (70.9–81.4)	76.1 (67.9–80)	57.3 (46.4–66.6)	4593	0.006	0.024	
% Time CPP < 60 mmHg	4.27 (1.14–9.01)	5.6 (2.11–19.8)	61.9 (32.9–66.3)	8299	0.002	0.009	
% Time CPP > 70 mmHg	68.1 (51.5–86.5)	74.8 (45.3–86.5)	16.1 (10.4–37.2)	4984	0.048	0.096	
Mean PRx	0.108 (− 0.00288–0.216)	0.135 (− 0.0105–0.287)	0.421 (0.335–0.646)	7695	0.020	0.050	
% Time PRx > 0	60.7 (48.2–73.4)	61.6 (49.7–81.4)	84.9 (77.6–91.4)	7637	0.016	0.049	
% Time PRx > 0.25	35.8 (24.6–48.6)	40.2 (25–57.2)	70.5 (62.7–83.6)	7734	0.018	0.050	
% Time PRx > 0.35	27.1 (17.4–38.7)	31.5 (17.5–45.9)	65.1 (55.9–80)	7761	0.014	0.047	
% Time ICP > 20 mmHg & PRx > 0.35	1.66 (0.215–4.88)	19.6 (11.7–30.7)	61 (41.9–73.8)	11,711	0.002	0.009	
Mean PAx	− 0.0269 (− 0.123–0.097)	0.0208 (− 0.137–0.253)	0.271 (0.0578–0.56)	7620	0.026	0.058	
% Time PAx > 0	46.8 (34.9–61.7)	49.8 (32.9–80)	73.5 (57.5–90.3)	7655	0.020	0.050	
% Time PAx > 0.2	26.2 (16.5–40.3)	33.2 (15.8–59)	57.2 (34.4–82.5)	7727	0.022	0.052	
% Time PAx > 0.25	21.6 (13.7–34.9)	29.3 (12.8–53)	53.7 (28.6–80.1)	7760	0.010	0.036	
% Time ICP > 20 mmHg & PAx > 0.25	1.27 (0.133–4.02)	18.7 (7.92–36.6)	41.8 (23–72.7)	11,707	0.002	0.009	
Mean RAC	− 0.29 (− 0.447 to − 0.109)	− 0.332 (− 0.522 to − 0.176)	− 0.0242 (− 0.114 to 0.225)	6940	0.206	0.330	
% Time RAC > 0	21.8 (11.8–36.6)	18.8 (8.46–33)	50.4 (36.8–62.9)	7016	0.156	0.271	
% Time ICP > 20 mmHg & RAC > 0	0.705 (0.0888–2.41)	10.6 (4.58–26.2)	38.4 (30.5–60.9)	11,528	0.002	0.009	
Mean RAP	0.668 (0.513–0.773)	0.707 (0.573–0.804)	0.732 (0.658–0.781)	7093	0.150	0.271	
% Time RAP > 0.40	82 (68.3–90.5)	86.4 (75.3–94.6)	90.2 (83.2–93)	7501	0.036	0.076	
rSO2*	70.1 (64.3–75.6)	67.6 (58.8–75)	70.8 (70.8–70.8)	293	0.652	0.767	
Mean COx*	0.0164 (− 0.0203–0.0758)	− 0.0045 (− 0.00788–0.00588)	0.159 (0.159–0.159)	335	0.852	0.897	
% Time COx > 0.20*	23.6 (17.8–31.2)	13.3 (12.4–17.5)	41.3 (41.3–41.3)	272	0.376	0.485	
Mean COx_a*	0.0611 (0.0147–0.114)	0.00657 (0.00593–0.022)	0.166 (0.166–0.166)	217	0.598	0.725	
% Time COx_a > 0.20*	28.8 (22–37.5)	16.1 (14.8–23.4)	37.2 (37.2–37.2)	190	0.352	0.469	
Mean PbtO2 (mmHg)†	22.9 (13.8–31.2)	25.4 (20.6–31.7)	13.2 (9.74–19)	917	0.792	0.856	
% Time PbtO2 < 15 mmHg†	7.27 (1.6–72.2)	3.46 (0.955–10.6)	61.7 (28.1–93)	924	0.730	0.818	
% Time PbtO2 < 20 mmHg†	30.5 (7.26–91.2)	15.8 (6.09–33.2)	74.7 (50.9–99.4)	970	0.912	0.930	
ABP arterial blood pressure, AMP pulse amplitude of ICP, COx cerebral oxygenation index (correlation between rSO2 and CPP), COx_a cerebral oxygenation index (correlation between rSO2 and ABP), CPP cerebral perfusion pressure, CT computed tomography, GCS Glasgow Coma Scale, ICP intracranial pressure, IQR interquartile range, J–T Jonckheere–Terpstra test, MAP mean arterial pressure, PAx pulse amplitude index (correlation between AMP and MAP), PbtO2 brain tissue oxygen tension, PRx pressure reactivity index (correlation between ICP and MAP), RAC correlation (R) between slow waves of AMP (A) and CPP (C), RAP compensatory reserve index (correlation between AMP and ICP), rSO2 regional cerebral oxygen saturation

Both unadjusted and adjusted p values are presented. Adjusted p values were calculated using the False Discovery Rate (FDR) method. Bolded p values are those reaching statistical significance, p < 0.05

*Only 146 patients had rSO2 data available

†Only 116 patients had PbtO2 data available

CPP

Upon Jonckheere–Terpstra testing for CPP trichotomization, which is summarized in Table 2, it was observed that decreasing CPP demonstrates a directional relationship with greater % time with PRx, PAx, and RAC above thresholds (p values range between 0.002 and 0.042), and % time with PbtO2 < 15 and 20 mmHg (p = 0.014, 0.004). Notably, CPP did not demonstrate a directional relationship with time spent with ICP above thresholds. When trichotomization was done using higher thresholds, creating groupings of < 70 mmHg, 70–80 mmHg, and > 80 mmHg, very similar results can be observed. The results of this sub-analysis can be found in Supplemental Appendix E.Table 2 Jonckheere–Terpstra Testing for CPP Trichotomization

Variable	CPP < 60 mmHg (n = 16)	60 mmHg ≤ CPP ≤ 70 mmHg (n = 69)	CPP > 70 mmHg (n = 288)	J–T statistic	p-value	Adjusted p-value	
Age (years)	40.5 (21.8–56.2)	35 (23–55)	39 (25–55)	13,521	0.330	0.426	
Sex (% male)	81.25%	65.22%	80.84%	14,198	0.026	0.061	
Admission GCS	3 (3–7)	6 (4–7)	6 (3–7)	10,746	0.748	0.787	
Admission GCS—motor	4 (1–5)	4 (3–5)	3 (1–5)	5148	0.148	0.211	
Admission pupil response (% bilaterally reactive)	26.67%	13.04%	15.41%	13,736	0.028	0.062	
Marshall CT grade	3.5 (3–4)	4.5 (2–5)	3 (2–5)	9782	0.020	0.053	
GOS	1 (1–1)	4 (1–5)	4 (1–5)	11,376	0.352	0.426	
Number with hypoxic episode	50%	30.61%	25.90%	4538	0.280	0.373	
Number with hypotensive episode	25%	10.20%	17.07%	5065	0.500	0.541	
Duration of recording (hours)	36.3 (16.8–105)	71.3 (45.9–116)	114 (66.1–200)	16,893	0.002	0.009	
Mean MAP (mmHg)	82.1 (73.3–87.3)	80.2 (76.9–84)	90.5 (85.2–95.8)	21,025	0.002	0.009	
Mean ICP (mmHg)	21.6 (16.5–32.9)	12.9 (9.68–16.1)	12.3 (8.16–15.5)	9905	0.004	0.013	
% Time ICP > 20 mmHg	63.9 (25.2–82.7)	1.97 (0.226–18.6)	5.01 (0.905–17)	11,456	0.112	0.172	
% Time ICP > 22 mmHg	44.9 (21.8–75.4)	0.899 (0.0863–11.6)	2.57 (0.47–10.4)	12,047	0.418	0.464	
Mean CPP (mmHg)	56.7 (51.8–58.6)	67.5 (65.3–68.7)	77.3 (73.4–82.7)	25,584	0.002	0.009	
% Time CPP < 60 mmHg	65.1 (52.5–77)	15.2 (9.92–23.5)	3.12 (0.822–6.06)	1766	0.002	0.009	
% Time CPP > 70 mmHg	9.34 (5.54–13.9)	32.6 (26.8–41.4)	74.3 (61.6–89.9)	25,299	0.002	0.009	
Mean PRx	0.417 (0.293–0.566)	0.14 (0.0376–0.253)	0.0921 (− 0.0161–0.212)	9190	0.002	0.009	
% Time PRx > 0	84.9 (72.2–90)	64 (55–76.7)	59.4 (46.7–71)	9321	0.002	0.009	
% Time PRx > 0.25	70.5 (57.8–78.8)	40.8 (26.8–56.8)	34.9 (23.6–47.1)	9475	0.002	0.009	
% Time PRx > 0.35	63.8 (50–75.5)	30.1 (21.2–45.1)	26.4 (16.6–37)	9588	0.002	0.009	
% Time ICP > 20 mmHg & PRx > 0.35	34.2 (12.8–63.2)	1.25 (0.0843–7.38)	2.13 (0.388–6.1)	11,075	0.050	0.087	
Mean PAx	0.173 (0.0292–0.377)	0.0171 (− 0.171–0.16)	− 0.0311 (− 0.125–0.0967)	10,970	0.042	0.080	
% Time PAx > 0	72.8 (53.1–84.8)	49 (33.9–68.7)	46 (35.1–61.5)	10,943	0.026	0.061	
% Time PAx > 0.2	51.2 (32.4–73.9)	29.5 (16–44.7)	25.2 (16.5–40.5)	10,928	0.042	0.080	
% Time PAx > 0.25	43.4 (28.2–70.1)	25.1 (12.6–39.4)	21 (13.5–34.9)	10,946	0.034	0.072	
% Time ICP > 20 mmHg & PAx > 0.25	17 (6.78–51.9)	0.676 (0.0888–6.06)	1.76 (0.226–4.64)	11,392	0.130	0.193	
Mean RAC	− 0.109 (− 0.242–0.142)	− 0.242 (− 0.44 to − 0.0153)	− 0.302 (− 0.467 to − 0.146)	9993	0.004	0.013	
% Time RAC > 0	37.5 (25.4–64.1)	23.2 (12.5–47.4)	21.6 (10.9–34.1)	10,532	0.012	0.037	
% Time ICP > 20 mmHg & RAC > 0	21.7 (4.63–47.7)	0.493 (0.0281–3.41)	0.882 (0.14–2.68)	11,232	0.068	0.113	
Mean RAP	0.655 (0.49–0.727)	0.627 (0.534–0.746)	0.68 (0.517–0.787)	14,353	0.086	0.138	
% Time RAP > 0.40	81.1 (66.3–87.7)	79.3 (70.2–90.1)	83 (71.1–91)	13,639	0.356	0.426	
rSO2*	70.8 (65.4–74)	69.8 (61.6–75)	70.4 (64.7–76.1)	2042	0.394	0.450	
Mean COx*	0.108 (− 0.008–0.109)	0.0242 (− 0.00451–0.0705)	0.012 (− 0.025–0.0714)	1816	0.362	0.426	
% Time COx > 0.20*	35.7 (18.5–36.2)	22.1 (15.1–30.5)	24 (17.6–31)	2060	0.860	0.860	
Mean COx_a*	0.0854 (0.0528–0.109)	0.0437 (0.00813–0.118)	0.0599 (0.0226–0.111)	1815	0.768	0.788	
% Time COx_a > 0.20*	28.4 (24.3–33.2)	26.3 (18.4–37.1)	29 (23.3–37.7)	2028	0.186	0.257	
Mean PbtO2 (mmHg)†	19 (13.2–31.2)	14.9 (9.98–19.9)	24 (15.5–31.7)	900	0.044	0.080	
% Time PbtO2 < 15 mmHg†	28.1 (1.88–61.7)	89.3 (41.7–95.3)	5.93 (1.5–61.9)	434	0.014	0.040	
% Time PbtO2 < 20 mmHg†	50.9 (23.2–74.7)	96.4 (87.1–98.9)	26 (6.24–88.4)	397	0.004	0.013	
AMP pulse amplitude of ICP, COx cerebral oxygenation index (correlation between rSO2 and CPP), COx_a cerebral oxygenation index (correlation between rSO2 and ABP), CPP cerebral perfusion pressure, CT computed tomography, GCS Glasgow Coma Scale, ICP intracranial pressure, IQR interquartile range, J–T Jonckheere–Terpstra test, MAP mean arterial pressure, PAx pulse amplitude index (correlation between AMP and MAP), PbtO2 brain tissue oxygen tension, PRx pressure reactivity index (correlation between ICP and MAP), RAC correlation (R) between slow waves of AMP (A) and CPP (C), RAP compensatory reserve index (correlation between AMP and ICP), rSO2 regional cerebral oxygen saturation

Both unadjusted and adjusted p values are presented. Adjusted p values were calculated using the False Discovery Rate (FDR) method. Bolded p values are those reaching statistical significance, p < 0.05

*Only 146 patients had rSO2 data available

†Only 116 patients had PbtO2 data available

Cerebrovascular reactivity metrics

Testing for PRx trichotomization demonstrated that, with increasing PRx, there is greater % time with CPP < 60 mmHg (p = 0.030), greater % time with RAP > 0.40 (p = 0.002), greater % time with PbtO2 below its thresholds (p = 0.024, 0.040), and less % time with CPP > 70 mmHg (p = 0.002). However, no directional relationship with ICP was found. These findings are summarized in Table 3. Increasing PAx demonstrated similar results; however, was found to be associated with greater % time with ICP above thresholds (p = 0.032, 0.040) and not with % time with RAP > 0.40. The Jonckheere–Terpstra testing results for PAx can be found in Supplemental Appendix F. RAC yielded differing results, only demonstrating directional relationships with less % time with CPP > 70 mmHg (p = 0.004) and greater % time with RAP > 0.40 (p = 0.002). The summary for these results can be found in Supplemental Appendix G.Table 3 Jonckheere–Terpstra Testing for PRx Trichotomization

Variable	Intact (PRx < 0) (n = 95)	Transitional (0 ≤ PRx ≤ 0.20) (n = 164)	Deranged (PRx > 0.20) (n = 114)	J–T statistic	p-value	Adjusted p-value	
Age (years)	33.5 (22.2–50.8)	37 (25–56)	42 (25–55)	24,310	0.062	0.092	
Sex (% male)	77.89%	77.44%	78.76%	22,557	0.886	0.933	
Admission GCS	6 (3–8)	6 (4–7)	6 (3–7)	18,716	0.778	0.871	
Admission GCS—motor	3 (1–5)	4 (1–5)	4 (1–5)	10,511	0.384	0.466	
Admission pupil response (% bilaterally reactive)	15.22%	12.96%	19.27%	19,485	0.052	0.080	
Marshall CT grade	3 (2–4)	3 (2–5)	3 (2–5)	23,339	0.004	0.009	
GOS	4 (1–5)	4 (1–5)	2 (1–5)	16,177	0.006	0.013	
Number with hypoxic episode	18.03%	28.57%	35.94%	8973	0.022	0.042	
Number with hypotensive episode	13.56%	14.29%	20.31%	8253	0.302	0.378	
Duration of recording (hours)	141 (75.9–242)	96.9 (55.3–168)	74.7 (39.3–165)	17,879	0.002	0.005	
Mean MAP (mmHg)	91 (82.6–96.7)	87.2 (81.8–93.8)	86.5 (81.1–91.7)	19,263	0.002	0.005	
Mean ICP (mmHg)	13.3 (9.67–17.2)	11.8 (8.17–15)	13.3 (8.72–17.7)	22,446	0.960	0.960	
% Time ICP > 20 mmHg	6.62 (1.31–24.3)	3.53 (0.385–15.7)	6.43 (0.852–29.3)	22,787	0.834	0.902	
% Time ICP > 22 mmHg	3.6 (0.872–14)	2.08 (0.188–9.21)	3.62 (0.421–18.2)	22,642	0.926	0.950	
Mean CPP (mmHg)	76.6 (71.4–81.9)	75.3 (70.8–82)	73.2 (67.5–78)	18,331	0.002	0.005	
% Time CPP < 60 mmHg	3.88 (1.35–7.97)	3.92 (0.848–8.16)	6.05 (1.78–17.1)	25,150	0.030	0.050	
% Time CPP > 70 mmHg	75.2 (57.3–89.3)	69.3 (52.7–88.3)	58.9 (33.5–74)	17,821	0.002	0.005	
Mean PRx	− 0.0814 (− 0.131 to − 0.0345)	0.101 (0.0512–0.14)	0.321 (0.251–0.434)	45,106	0.002	0.005	
% Time PRx > 0	38.6 (34.3–44)	60.2 (55–64.3)	81.7 (76.5–87.8)	44,708	0.002	0.005	
% Time PRx > 0.25	19 (14.7–22.4)	35.4 (29.9–40)	61.9 (53.9–72.9)	44,587	0.002	0.005	
% Time PRx > 0.35	13.2 (9.95–16.2)	26.7 (22.2–30.5)	51.3 (42.2–65.2)	44,147	0.002	0.005	
% Time ICP > 20 mmHg & PRx > 0.35	1.75 (0.468–4.21)	1.63 (0.205–5.42)	4.76 (0.367–17)	26,227	0.004	0.009	
Mean PAx	− 0.147 (− 0.228 to − 0.0881)	− 0.0285 (− 0.118–0.0576)	0.129 (0.0408–0.289)	36,995	0.002	0.005	
% Time PAx > 0	31.4 (23.8–38.4)	46.7 (35.4–57.3)	66 (56.4–78.1)	37,366	0.002	0.005	
% Time PAx > 0.2	15.7 (11–19.8)	25.3 (17.6–34.3)	44.6 (34.6–60.4)	37,642	0.002	0.005	
% Time PAx > 0.25	12.5 (8.51–16.1)	21.3 (14.5–29.4)	39.6 (30.4–55.7)	37,549	0.002	0.005	
% Time ICP > 20 mmHg & PAx > 0.25	1.62 (0.218–4.74)	1.25 (0.139–3.66)	2.98 (0.227–12.6)	25,148	0.026	0.045	
Mean RAC	− 0.471 (− 0.59 to − 0.328)	− 0.302 (− 0.44 to − 0.16)	− 0.0977 (− 0.275 to 0.0843)	34,604	0.002	0.005	
% Time RAC > 0	10.2 (5.93–19.7)	21.7 (12.9–32.1)	39.1 (23.5–58.6)	34,525	0.002	0.005	
% Time ICP > 20 mmHg & RAC > 0	0.877 (0.212–2.46)	0.713 (0.0856–2.53)	1.67 (0.221–9.23)	25,595	0.014	0.028	
Mean RAP	0.74 (0.635–0.839)	0.66 (0.507–0.757)	0.627 (0.47–0.723)	16,727	0.002	0.005	
% Time RAP > 0.40	89.4 (80–94.8)	81.7 (67.6–89.2)	78.9 (65.2–88.5)	17,177	0.002	0.005	
rSO2*	70.4 (64.6–74.5)	69.8 (64.2–76.6)	70.8 (63.4–75.6)	2997	0.784	0.871	
Mean COx*	0 (− 0.0229–0.0488)	0.0166 (− 0.0109–0.0909)	0.0178 (− 0.00187–0.0726)	3689	0.152	0.212	
% Time COx > 0.20*	21.5 (13.2–28.1)	24.5 (18.3–33.3)	22.3 (18.1–31.1)	3660	0.228	0.304	
Mean COx_a*	0.0485 (0.012–0.0946)	0.0572 (0.0145–0.117)	0.0721 (0.0136–0.117)	3003	0.286	0.369	
% Time COx_a > 0.20*	26.7 (20.2–32.5)	29.1 (23.5–37.4)	28.5 (21.4–37.7)	2962	0.538	0.633	
Mean PbtO2 (mmHg)†	25.3 (21.7–31.7)	22.7 (13.5–31.6)	20 (13.7–27.7)	1874	0.154	0.212	
% Time PbtO2 < 15 mmHg†	1.77 (0.893–10.6)	12.1 (1.72–75.1)	17.5 (4.17–80.8)	2594	0.024	0.044	
% Time PbtO2 < 20 mmHg†	15.8 (5.93–36.5)	37 (5.09–94.2)	50 (23.2–90.7)	2568	0.040	0.064	
AMP pulse amplitude of ICP, COx cerebral oxygenation index (correlation between rSO2 and CPP), COx_a cerebral oxygenation index (correlation between rSO2 and ABP), CPP cerebral perfusion pressure, CT computed tomography, GCS Glasgow Coma Scale, ICP intracranial pressure, IQR interquartile range, J–T Jonckheere–Terpstra test, MAP mean arterial pressure, PAx pulse amplitude index (correlation between AMP and MAP), PbtO2 brain tissue oxygen tension, PRx pressure reactivity index (correlation between ICP and MAP), RAC correlation (R) between slow waves of AMP (A) and CPP (C), RAP compensatory reserve index (correlation between AMP and ICP), rSO2 regional cerebral oxygen saturation

Both unadjusted and adjusted p values are presented. Adjusted p values were calculated using the False Discovery Rate (FDR) method. Bolded p values are those reaching statistical significance, p < 0.05

*Only 146 patients had rSO2 data available

†Only 116 patients had PbtO2 data available

Oxygen delivery metrics

Next, Jonckheere–Terpstra testing for PbtO2 found that, with decreasing values, there was greater % time with CPP < 60 mmHg (p = 0.002), less % time with CPP > 70 mmHg (p = 0.002), greater % time with PAx and RAC above their literature defined thresholds (p values range between 0.020 and 0.048), and greater % time with COx > 0.20 (p = 0.020). These results can be found in Supplemental Appendix H. Testing for rSO2 only demonstrated a directional relationship with greater % time with PAx above its thresholds (p values range between 0.036 and 0.049), see Supplemental Appendix I.

Generated plots

Histograms illustrating the spread of various insult burden metrics between the three groupings for ICP, CPP, PRx, PbtO2, and rSO2 can be found in Supplemental Appendices J–N. In Fig. 1 we display stacked bar plots that compare the distribution of % time with key cerebral physiologic metrics in various ranges between trichotomized patients. Panels A–C demonstrate that with increasing ICP, there tends to be greater % time with CPP < 60 mmHg and PRx > 0.20, but that no clear directional relationship with PbtO2 is observable. Panels D–F illustrate that with low CPP, there tends to be greater % time with ICP > 25 mmHg, and PRx > 0.20, but again, no clear directional relationship with PbtO2 is observed.Fig. 1 Stacked bar plots comparing cerebral physiology between patients trichotomized using mean ICP or CPP. A comparison of % times with CPP in three ranges between patients trichotomized using mean ICP; B comparison of % times with PRx in three ranges between patients trichotomized using mean ICP; C comparison of % times with PbtO2 in three ranges between patients trichotomized using mean ICP; D comparison of % times with ICP in three ranges between patients trichotomized using mean CPP; E comparison of % times with PRx in three ranges between patients trichotomized using mean CPP; F comparison of % times with PbtO2 in three ranges between patients trichotomized using mean CPP. AMP pulse amplitude of ICP, CPP cerebral perfusion pressure, ICP intracranial pressure, MAP mean arterial pressure, PbtO2 brain tissue oxygen tension, PRx pressure reactivity index (correlation between ICP and MAP)

Contour plots demonstrating the effects that cerebrovascular reactivity intactness has on the relationship between the above mentioned physiologic metrics and metrics of insult burden can be found in Supplemental Appendices O–R. Figure 2 displays some of the key plots that demonstrate the protective effects of intact cerebrovascular reactivity on insult burden. Panels A and B show that greater mean ICP is associated with more time spent with CPP < 60 mmHg as well as more time spent with PbtO2 < 20 mmHg, but that these relationships are stronger when PRx is positive and diminish when PRx is negative. Similarly, panel C illustrates that low PbtO2 is associated with greater % time with CPP < 60 mmHg when PRx is deranged. Interestingly, panel D shows that % time with CPP > 70 mmHg is associated with high PbtO2, and that intact PRx maintains this relationship to a further extent.Fig. 2 Contour plots demonstrating the protective effects of preserved cerebrovascular reactivity on global cerebral insult burden. Plots illustrate the effects of PRx on the relationship between: A ICP and % time with CPP < 60 mmHg; B ICP and % time with PbtO2 < 20 mmHg; C PbtO2 and % time with CPP < 60 mmHg; and D PbtO2 and % time with CPP > 70 mmHg. Data points used to construct the contour plots are overlayed on each plot. CPP cerebral perfusion pressure, ICP intracranial pressure, PbtO2 brain tissue oxygen tension, PRx pressure reactivity index

Discussion

In this descriptive analysis on the effects of derangements in continuous multimodal cerebral physiology on cerebral physiologic insult burden, we were able to uncover multiple interesting findings that deserve highlighting. Firstly, we found that increasing ICP is associated with increasing burden of cerebral hypoperfusion, deranged cerebrovascular reactivity, and reduced cerebral compliance. This is in keeping with the findings of a 2020 study by Zeiler and colleagues, where the authors compared cerebral physiology between patients with mean ICP < 15 mmHg and those with mean ICP > 20 mmHg [23]. This study, however, found that elevated ICP was also associated with worse PbtO2, while our study failed to find such an association. This discrepancy could potentially be explained by the low proportion of patients in our cohort who had PbtO2 monitored. In total, only 116 patients had this metric monitored during their ICU stay and, therefore, analyses involving PbtO2 may have been too underpowered to undercover this relationship.

Next, our analysis indicated that decreasing CPP is associated with increased time suffering from deranged cerebrovascular reactivity and low PbtO2. The fact that these directional relationships were found is interesting, as it suggests that higher mean CPP is associated with less cerebral physiologic insult burden. This is further suggested by finding that cerebral hyperperfusion, as defined as CPP > 70 mmHg, was associated with lower mean ICP. This is somewhat surprising, considering that current management guidelines recommend maintaining CPP below this threshold, suggesting that it contributes to secondary brain injury [10, 11]. Further, it was previously believed that having CPP above 70 mmHg may be associated with a range of systematic complications, such as acute respiratory distress syndrome (ARDS). However, these findings are actually in keeping with recent literature that suggests that, though preventing hypoperfusion is vital, preventing hyperemic CPP may not significantly affect outcomes [36, 37]. Thiara et al. found that time spent with CPP above CPP optimal (CPPopt) is not associated with acute respiratory distress syndrome (ARDS) [37]. Furthermore, a recent study by our group even suggested that spending time with elevated CPP may actually be associated with improvement in outcome, possibly due to the injured brain requiring greater blood flow to fulfil increased metabolic activity associated with injury repair [38]. This contributes to an increasing body of literature that questions the utility of a 70 mmHg CPP threshold. Additionally, the association found between low ICP and more cerebral hyperperfusion can be explained with the CPP derivation formula: CPP = MAP–ICP. Interestingly, no association between CPP and burden of intracranial hypertension was uncovered. This may be explained by the fact that ICP is highly controlled during moderate-to-severe TBI management, with our cohort having an average % time with elevated ICP of only about 5%.

Our analysis of the three ICP-based cerebrovascular reactivity indices yielded unexpectedly differing results. Increasing (deranged) PRx was found to be associated with more time suffering from cerebral hypoperfusion, poor cerebral compliance (as measured using RAP), and low PbtO2, and less time with cerebral hyperperfusion. This supports the growing narrative that PRx monitoring can provide valuable insight that can help minimize secondary brain injury [39, 40]. Increasing PAx displayed somewhat similar results but was also found to be associated with more time suffering from intracranial hypertension; however, was not found to be associated with poor cerebral compliance. Increasing mean RAC, on the other hand, was only found to be related to less time with cerebral hyperperfusion and greater time with poor cerebral compliance. These inconsistent findings suggest that these three indices offer different insights into a patient’s cerebral physiology and have different utility. This variation may be explained by the fact that RAC reflects both cerebrovascular reactivity and cerebral compliance [23], and that PAx and RAC (but not PRx) utilize AMP for derivation. The ICP-based cerebrovascular reactivity indices did not demonstrate associations with NIRS-based indices. This suggests that these NIRS-based indices may not closely mirror ICP-based indices for the evaluation of cerebral autoregulatory status.

Looking at the results for PbtO2 trichotomization, it was shown that decreasing mean values were only associated with more time suffering from cerebral hypoperfusion, more time with PAx and RAC above thresholds, more time with COx above threshold, and less time with cerebral hyperperfusion. Overall, it seems that PbtO2 offers mixed insight into cerebral physiologic insult burden. This finding is supported by a recent study by Svedung Wettervik and colleagues, which could only find weak associations between cerebral physiologic variables and PbtO2 [41]. It is interesting that an association was found with PAx and RAC, but not with PRx; however, this may again be due to the low sample size of patients with PbtO2 monitoring. It is possible that the lack of association between PbtO2 and insult burden metrics can be partially explained by the fact that low/deranged PbtO2 can often be relatively quickly treated with oxygen supplementation, thus reducing the incidence of low PbtO2 with other deranged cerebral physiology. This could potentially weaken any relationships between PbtO2 and measures of cerebral physiologic insult burden. The lack of associations between this cerebral oxygen delivery measure and insult burden metrics may also suggest that different pathophysiologic mechanisms are at play. It is possible that deranged cerebral oxygen delivery causes insult through separate mechanisms from other drivers of secondary brain injury. However, their lack of associations with outcomes, as seen in Supplemental Appendix D, also suggests a general lack of association with secondary brain injury.

With regard to PbtO2, it is important to acknowledge the complex nature of this measure, which is influenced by a wide range of physiological factors. PbtO2 is not solely a reflection of cerebral oxygen delivery. While it is influenced by arterial oxygen tension (PbtO2) and CBF, PbtO2 is better described as an indicator of the balance between regional oxygen supply and cellular oxygen consumption [42]. A large range of factors can contribute to changes in this balance. Factors such as the diffusion distance between capillaries and cells, the location of the probe relative to arterioles and venules, hemoglobin concentration, vascular reactivity, metabolic demand, and secondary brain injury can all contribute to variations in PbtO2 readings. Understanding the complexity of the interplay of factors influencing PbtO2 is crucial for interpreting PbtO2 results.

Testing for rSO2 demonstrated even poorer results, with no associations with any of the cerebral physiologic insult burden metrics, except time spent with PAx above its thresholds. This suggests that raw rSO2 values offer limited insight into secondary brain injury. A recent study from the CAHR-TBI consortium by Gomez and colleagues supports this finding as we found that raw rSO2 demonstrates limited prognostic utility [27]. Though there is some interest in the clinical application of NIRS in TBI management, the role of NIRS in this setting is arguably very limited as a result of various major limitations of the technology. NIRS devices use near-infrared light, which is able to penetrate through the scalp and skull into the cerebral parenchyma where it is absorbed and reflected by hemoglobin in the microvasculature. Then by detecting the intensity of light, at specific wavelengths, that is scattered and reflected back to the device, the relative concentrations of oxygenated and deoxygenated hemoglobin can be determined [43, 44]. These relative concentrations can then be used to derive the regional cerebral oxygen saturation (rSO2). The most significant limitation of NIRS technology arises from the problem of extracerebral interference from sources such as the scalp, bone, cerebrospinal fluid, and subdural blood [45]. There is significant homogeneity in these structures between patients, as well as across the skull. This results in relatively large amounts of variation in signal depending on the placement of the pads and patient-specific factors. This raises questions about the validity of NIRS-based values and their clinical utility.

Finally, the generated contour plots strongly suggest that intact cerebrovascular reactivity has protective effects on the relationships uncovered in this analysis. This finding has been highlighted in multiple recent studies [9, 46–48], promoting the importance of maintaining cerebrovascular reactivity in order to minimize secondary brain insult.

This study provides a unique comprehensive assessment of the various associations that cerebral physiologic derangements have with cerebral physiologic insult burden. The results above shed unique light on the important relationship that cerebral physiology as a whole has with secondary brain injury following moderate-to-severe TBI. We have provided supporting evidence of the importance of ICP, CPP, and cerebrovascular reactivity control in minimizing secondary brain injury. Our analysis also raises some questions of the utility of PbtO2 and rSO2 monitoring, in their raw signal output form, in detecting and protecting against secondary brain injury.

Limitations

Despite the important findings of this analysis, a couple of important limitations must be highlighted. Firstly, though this study utilized a large multi-centered cohort, only 116 patients had PbtO2 monitored and were included in analyses involving this parameter. This may have limited our ability to find associations between PbtO2 and other cerebral physiologic parameters. Next, our analysis utilized grand-averaged values. Such values fail to accurately reflect the state of the parameter over the patient’s time in the ICU. For example, a patient who has extremely high CPP for half their recording period and extremely low CPP for the other half, may have a relatively moderate mean CPP value. Additionally, acute extreme derangements in physiology can be diluted if the recording period is long enough. Thus, future works should focus on using metrics that better reflect the actual cerebral physiologic picture of patients, such as dose-time above/below thresholds. Another limitation of this study is that it could have included more continuous multimodal cerebral physiologic monitoring modalities, such as electroencephalogram and bispectral index score. This could have offered a fuller understanding of the effects of deranged cerebral physiology on insult burden.

Conclusion

In this multi-centered descriptive analysis, we evaluated the associations between derangements in continuous multimodal cerebral physiology and cerebral physiologic insult burden. We found that mean ICP, CPP, and ICP-based cerebrovascular reactivity indices demonstrated statistically significant associations with global cerebral physiologic insult burden. However, it remains unclear whether measures of oxygen delivery provide any meaningful insight into such insult burden.

Supplementary Information

Supplementary Material 1.

Abbreviations

AMP Pulse amplitude of ICP

ABP Arterial blood pressure

BTF Brain Trauma Foundation

CAHR-TBI Canadian High Resolution-TBI Research Collaborative

COx Correlation between rSO2 and CPP

COx_a Correlation between rSO2 and ABP

CPP Cerebral perfusion pressure

EVD External ventricular drain

GCS Glasgow Coma Scale

GOS Glasgow Outcome Scale

ICM+ Intensive Care Monitoring “Plus” software

ICP Intracranial pressure

ICU Intensive care unit

IQR Interquartile range

FDR False discovery rate

MAP Mean arterial pressure

NIRS Near-infrared spectroscopy

PbtO2 Brain tissue oxygenation

PAx Pulse amplitude index

PRx Pressure reactivity index

RAC Correlation (R) between AMP (A) and CPP (C)

RAP The correlation (R) between AMP (A) and ICP (P)

rSO2 Regional cerebral oxygen saturation

TBI Traumatic brain injury

Acknowledgements

Not applicable.

Author contributions

KYS.: Investigation, Formal Analysis, Data Curation, Writing; AG: Data Curation, Writing; DG: Data Curation, Writing; MS: Data Curation, Writing; FB: Data Curation, Writing; CG: Data Curation, Writing; EPT: Data Curation, Writing; RR: Data Curation, Writing; MA: Data Curation, Writing; LF: Data Curation, Writing; AK: Data Curation, Writing; FAZ: Conceptualization, Data Curation, Writing, Supervision, Funding acquisition.

Funding

This work was directly supported through the Natural Sciences and Engineering Research Council of Canada (NSERC; ALLRP-576386-22 and ALLRP-586244-23) and the University of Manitoba Endowed Manitoba Public Insurance (MPI) Chair in Neuroscience. FAZ is supported through the Endowed MPI Chair in Neuroscience/TBI Research Endowment, NSERC (DGECR-2022-00260, RGPIN-2022-03621, ALLRP-578524-22, ALLRP-576386-22, I2IPJ 586104-23, and ALLRP 586244-23), Canadian Institutes of Health Research (CIHR), the MPI Neuroscience Research Operating Fund, the Health Sciences Centre Foundation Winnipeg, the Canada Foundation for Innovation (CFI) (Project #: 38583), Research Manitoba (Grant #: 3906 and 5429) and the University of Manitoba Vice President of Research and Innovation (VPRI) Research Investment Fund (RIF). KYS is supported through the NSERC Canada Graduate Scholarships-Doctoral program (CGS D-579021-2023), the University of Manitoba R.G. and E.M. Graduate Fellowship (Doctoral) in Biomedical Engineering, and the University of Manitoba MD/PhD program. AG is supported through a CIHR Fellowship (Grant #: 472286). EPT acknowledges funding support from Karolinska Institutet Funds (2022-01576), Hjärnfonden/Swedish Brain Foundation (FO2023-0124), Svenska Läkaresällskapet/The Swedish Society of Medicine (SLS-985504) and Region Stockholm Clinical Research Appointment (ALF Klinisk Forskare, FoUI-981490). RR acknowledges funding support from Helsinki University Hospital, Finska Läkaresällskapet, Medicinska Understödsföreningen Liv och Hälsa, and Svenska Kulturfonden. LF is supported by the NSERC Post-Doctoral Fellowship (PDF) program.

Availability of data and materials

The datasets analyzed in this study are currently not publicly available as the Canadian and EU jurisdictions, including the research ethics boards and regional privacy bodies under which data was collected, do not allow for data sharing.

Declarations

Ethics approval and consent to participate

Ethics approval in regard to all aspects of data collection and anonymous data transfer between centers for this database has been granted by each site’s local research ethics board: University of Manitoba Biomedical Research Ethics Board (BREB, H2017:181, H2017:188, H2020:118, B2023:001), University of Calgary Conjoint Health Research Ethics Board (CHREB, H20-03759), University of British Columbia Clinical Research Ethics Board (CREB, REB20-0482) and University of Maastricht Medical Ethics Committee (16-4-243). As data collection is entirely anonymized, the respective research ethics boards have granted approval for data collection to operate under a waived consent model.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. McKee AC Daneshvar DH The neuropathology of traumatic brain injury Handb Clin Neurol 2015 127 45 66 10.1016/B978-0-444-52892-6.00004-0 25702209
McKee AC, Daneshvar DH. The neuropathology of traumatic brain injury. Handb Clin Neurol. 2015;127:45–66.25702209 10.1016/B978-0-444-52892-6.00004-0
2. Maas AIR Menon DK Adelson PD Andelic N Bell MJ Belli A Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research Lancet Neurol 2017 16 987 1048 10.1016/S1474-4422(17)30371-X 29122524
Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16:987–1048.29122524 10.1016/S1474-4422(17)30371-X
3. Rosenfeld JV Maas AI Bragge P Morganti-Kossmann MC Manley GT Gruen RL Early management of severe traumatic brain injury The Lancet 2012 380 1088 1098 10.1016/S0140-6736(12)60864-2
Rosenfeld JV, Maas AI, Bragge P, Morganti-Kossmann MC, Manley GT, Gruen RL. Early management of severe traumatic brain injury. The Lancet. 2012;380:1088–98.10.1016/S0140-6736(12)60864-2
4. Marshall LF Smith RW Shapiro HM The outcome with aggressive treatment in severe head injuries: part I: the significance of intracranial pressure monitoring J Neurosurg 1979 50 20 25 10.3171/jns.1979.50.1.0020 758374
Marshall LF, Smith RW, Shapiro HM. The outcome with aggressive treatment in severe head injuries: part I: the significance of intracranial pressure monitoring. J Neurosurg. 1979;50:20–5.758374 10.3171/jns.1979.50.1.0020
5. Saul TG Ducker TB Effect of intracranial pressure monitoring and aggressive treatment on mortality in severe head injury J Neurosurg 1982 56 498 503 10.3171/jns.1982.56.4.0498 6801218
Saul TG, Ducker TB. Effect of intracranial pressure monitoring and aggressive treatment on mortality in severe head injury. J Neurosurg. 1982;56:498–503.6801218 10.3171/jns.1982.56.4.0498
6. Miller JD Butterworth JF Gudeman SK Faulkner JE Choi SC Selhorst JB Further experience in the management of severe head injury J Neurosurg 1981 54 289 299 10.3171/jns.1981.54.3.0289 7463128
Miller JD, Butterworth JF, Gudeman SK, Faulkner JE, Choi SC, Selhorst JB, et al. Further experience in the management of severe head injury. J Neurosurg. 1981;54:289–99.7463128 10.3171/jns.1981.54.3.0289
7. Changaris DG McGraw CP Richardson JD Garretson HD Arpin EJ Shields CB Correlation of cerebral perfusion pressure and Glasgow Coma Scale to outcome J Trauma 1987 27 1007 1013 10.1097/00005373-198709000-00009 3656462
Changaris DG, McGraw CP, Richardson JD, Garretson HD, Arpin EJ, Shields CB. Correlation of cerebral perfusion pressure and Glasgow Coma Scale to outcome. J Trauma. 1987;27:1007–13.3656462 10.1097/00005373-198709000-00009
8. Rosner MJ Daughton S Cerebral perfusion pressure management in head injury J Trauma 1990 30 933 940 10.1097/00005373-199008000-00001 2117669
Rosner MJ, Daughton S. Cerebral perfusion pressure management in head injury. J Trauma. 1990;30:933–40 (discussion 940-941).2117669 10.1097/00005373-199008000-00001
9. Güiza F Meyfroidt G Piper I Citerio G Chambers I Enblad P Cerebral perfusion pressure insults and associations with outcome in adult traumatic brain injury J Neurotrauma 2017 34 2425 2431 10.1089/neu.2016.4807 28385097
Güiza F, Meyfroidt G, Piper I, Citerio G, Chambers I, Enblad P, et al. Cerebral perfusion pressure insults and associations with outcome in adult traumatic brain injury. J Neurotrauma. 2017;34:2425–31.28385097 10.1089/neu.2016.4807
10. Carney N Totten AM O’Reilly C Ullman JS Hawryluk GWJ Bell MJ Guidelines for the management of severe traumatic brain injury, fourth edition Neurosurgery 2017 80 6 15 10.1227/NEU.0000000000001432 27654000
Carney N, Totten AM, O’Reilly C, Ullman JS, Hawryluk GWJ, Bell MJ, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80:6–15.27654000 10.1227/NEU.0000000000001432
11. Hawryluk GWJ Aguilera S Buki A Bulger E Citerio G Cooper DJ A management algorithm for patients with intracranial pressure monitoring: the Seattle international severe traumatic brain injury consensus conference (SIBICC) Intensive Care Med 2019 45 1783 1794 10.1007/s00134-019-05805-9 31659383
Hawryluk GWJ, Aguilera S, Buki A, Bulger E, Citerio G, Cooper DJ, et al. A management algorithm for patients with intracranial pressure monitoring: the Seattle international severe traumatic brain injury consensus conference (SIBICC). Intensive Care Med. 2019;45:1783–94.31659383 10.1007/s00134-019-05805-9
12. Steyerberg EW Wiegers E Sewalt C Buki A Citerio G De Keyser V Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study Lancet Neurol 2019 18 923 934 10.1016/S1474-4422(19)30232-7 31526754
Steyerberg EW, Wiegers E, Sewalt C, Buki A, Citerio G, De Keyser V, et al. Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. Lancet Neurol. 2019;18:923–34.31526754 10.1016/S1474-4422(19)30232-7
13. Donnelly J Czosnyka M Adams H Cardim D Kolias AG Zeiler FA Twenty-five years of intracranial pressure monitoring after severe traumatic brain injury: a retrospective, single-center analysis Neurosurgery 2019 85 E75 82 10.1093/neuros/nyy468 30476233
Donnelly J, Czosnyka M, Adams H, Cardim D, Kolias AG, Zeiler FA, et al. Twenty-five years of intracranial pressure monitoring after severe traumatic brain injury: a retrospective, single-center analysis. Neurosurgery. 2019;85:E75-82.30476233 10.1093/neuros/nyy468
14. Lee J-M Grabb MC Zipfel GJ Choi DW Brain tissue responses to ischemia J Clin Invest 2000 106 723 731 10.1172/JCI11003 10995780
Lee J-M, Grabb MC, Zipfel GJ, Choi DW. Brain tissue responses to ischemia. J Clin Invest. 2000;106:723–31.10995780 10.1172/JCI11003
15. Bernard F Gallagher C Griesdale D Kramer A Sekhon M Zeiler FA The Canadian High-resolution traumatic brain injury (CAHR-TBI) research collaborative Can J Neurol Sci 2020 47 551 556 10.1017/cjn.2020.54 32174295
Bernard F, Gallagher C, Griesdale D, Kramer A, Sekhon M, Zeiler FA. The Canadian High-resolution traumatic brain injury (CAHR-TBI) research collaborative. Can J Neurol Sci. 2020;47:551–6.32174295 10.1017/cjn.2020.54
16. Chesnut R Videtta W Vespa P LeRoux P Participants in the international multidisciplinary consensus conference on multimodality monitoring. Intracranial pressure monitoring: fundamental considerations and rationale for monitoring Neurocrit Care 2014 21 Suppl 2 S64 84 10.1007/s12028-014-0048-y 25208680
Chesnut R, Videtta W, Vespa P, LeRoux P. Participants in the international multidisciplinary consensus conference on multimodality monitoring. Intracranial pressure monitoring: fundamental considerations and rationale for monitoring. Neurocrit Care. 2014;21(Suppl 2):S64-84.25208680 10.1007/s12028-014-0048-y
17. Thomas E Czosnyka M Hutchinson P Calculation of cerebral perfusion pressure in the management of traumatic brain injury: joint position statement by the councils of the Neuroanaesthesia and Critical Care Society of Great Britain and Ireland (NACCS) and the Society of British Neurological Surgeons (SBNS) Br J Anaesth 2015 115 487 488 10.1093/bja/aev233 26187435
Thomas E, Czosnyka M, Hutchinson P. Calculation of cerebral perfusion pressure in the management of traumatic brain injury: joint position statement by the councils of the Neuroanaesthesia and Critical Care Society of Great Britain and Ireland (NACCS) and the Society of British Neurological Surgeons (SBNS). Br J Anaesth. 2015;115:487–8.26187435 10.1093/bja/aev233
18. Calviello LA Czigler A Zeiler FA Smielewski P Czosnyka M Validation of non-invasive cerebrovascular pressure reactivity and pulse amplitude reactivity indices in traumatic brain injury Acta Neurochir (Wien) 2020 162 337 344 10.1007/s00701-019-04169-9 31853797
Calviello LA, Czigler A, Zeiler FA, Smielewski P, Czosnyka M. Validation of non-invasive cerebrovascular pressure reactivity and pulse amplitude reactivity indices in traumatic brain injury. Acta Neurochir (Wien). 2020;162:337–44.31853797 10.1007/s00701-019-04169-9
19. Calviello L Donnelly J Cardim D Robba C Zeiler FA Smielewski P Compensatory-reserve-weighted intracranial pressure and its association with outcome after traumatic brain injury Neurocrit Care 2018 28 212 220 10.1007/s12028-017-0475-7 29043546
Calviello L, Donnelly J, Cardim D, Robba C, Zeiler FA, Smielewski P, et al. Compensatory-reserve-weighted intracranial pressure and its association with outcome after traumatic brain injury. Neurocrit Care. 2018;28:212–20.29043546 10.1007/s12028-017-0475-7
20. Fraser CD Brady KM Rhee CJ Easley RB Kibler K Smielewski P The frequency response of cerebral autoregulation J Appl Physiol 2013 115 52 56 10.1152/japplphysiol.00068.2013 23681909
Fraser CD, Brady KM, Rhee CJ, Easley RB, Kibler K, Smielewski P, et al. The frequency response of cerebral autoregulation. J Appl Physiol. 2013;115:52–6.23681909 10.1152/japplphysiol.00068.2013
21. Howells T Johnson U McKelvey T Enblad P An optimal frequency range for assessing the pressure reactivity index in patients with traumatic brain injury J Clin Monit Comput 2015 29 97 105 10.1007/s10877-014-9573-7 24664812
Howells T, Johnson U, McKelvey T, Enblad P. An optimal frequency range for assessing the pressure reactivity index in patients with traumatic brain injury. J Clin Monit Comput. 2015;29:97–105.24664812 10.1007/s10877-014-9573-7
22. Czosnyka M Smielewski P Kirkpatrick P Laing RJ Menon D Pickard JD Continuous assessment of the cerebral vasomotor reactivity in head injury Neurosurgery 1997 41 11 17 10.1097/00006123-199707000-00005 9218290
Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D, Pickard JD. Continuous assessment of the cerebral vasomotor reactivity in head injury. Neurosurgery. 1997;41:11–7 (discussion 17-19).9218290 10.1097/00006123-199707000-00005
23. Zeiler FA Donnelly J Menon DK Smielewski P Hutchinson PJA Czosnyka M A description of a new continuous physiological index in traumatic brain injury using the correlation between pulse amplitude of intracranial pressure and cerebral perfusion pressure J Neurotrauma 2018 35 963 974 10.1089/neu.2017.5241 29212405
Zeiler FA, Donnelly J, Menon DK, Smielewski P, Hutchinson PJA, Czosnyka M. A description of a new continuous physiological index in traumatic brain injury using the correlation between pulse amplitude of intracranial pressure and cerebral perfusion pressure. J Neurotrauma. 2018;35:963–74.29212405 10.1089/neu.2017.5241
24. Sorrentino E Diedler J Kasprowicz M Budohoski KP Haubrich C Smielewski P Critical thresholds for cerebrovascular reactivity after traumatic brain injury Neurocrit Care 2012 16 258 266 10.1007/s12028-011-9630-8 21964774
Sorrentino E, Diedler J, Kasprowicz M, Budohoski KP, Haubrich C, Smielewski P, et al. Critical thresholds for cerebrovascular reactivity after traumatic brain injury. Neurocrit Care. 2012;16:258–66.21964774 10.1007/s12028-011-9630-8
25. Zeiler FA Lee JK Smielewski P Czosnyka M Brady K Validation of intracranial pressure-derived cerebrovascular reactivity indices against the lower limit of autoregulation, part II: experimental model of arterial hypotension J Neurotrauma 2018 35 2812 2819 10.1089/neu.2017.5604 29808745
Zeiler FA, Lee JK, Smielewski P, Czosnyka M, Brady K. Validation of intracranial pressure-derived cerebrovascular reactivity indices against the lower limit of autoregulation, part II: experimental model of arterial hypotension. J Neurotrauma. 2018;35:2812–9.29808745 10.1089/neu.2017.5604
26. Aries MJH Czosnyka M Budohoski KP Kolias AG Radolovich DK Lavinio A Continuous monitoring of cerebrovascular reactivity using pulse waveform of intracranial pressure Neurocrit Care 2012 17 67 76 10.1007/s12028-012-9687-z 22477613
Aries MJH, Czosnyka M, Budohoski KP, Kolias AG, Radolovich DK, Lavinio A, et al. Continuous monitoring of cerebrovascular reactivity using pulse waveform of intracranial pressure. Neurocrit Care. 2012;17:67–76.22477613 10.1007/s12028-012-9687-z
27. Gomez A Froese L Griesdale D Thelin EP Raj R van Iperenburg L Prognostic value of near-infrared spectroscopy regional oxygen saturation and cerebrovascular reactivity index in acute traumatic neural injury: a Canadian High-Resolution Traumatic Brain Injury (CAHR-TBI) Cohort Study Crit Care 2024 28 78 10.1186/s13054-024-04859-6 38486211
Gomez A, Froese L, Griesdale D, Thelin EP, Raj R, van Iperenburg L, et al. Prognostic value of near-infrared spectroscopy regional oxygen saturation and cerebrovascular reactivity index in acute traumatic neural injury: a Canadian High-Resolution Traumatic Brain Injury (CAHR-TBI) Cohort Study. Crit Care. 2024;28:78.38486211 10.1186/s13054-024-04859-6
28. Gomez A Sainbhi AS Stein KY Vakitbilir N Froese L Zeiler FA Statistical properties of cerebral near infrared and intracranial pressure-based cerebrovascular reactivity metrics in moderate and severe neural injury: a machine learning and time-series analysis Intensive Care Med Exp 2023 11 57 10.1186/s40635-023-00541-3 37635181
Gomez A, Sainbhi AS, Stein KY, Vakitbilir N, Froese L, Zeiler FA. Statistical properties of cerebral near infrared and intracranial pressure-based cerebrovascular reactivity metrics in moderate and severe neural injury: a machine learning and time-series analysis. Intensive Care Med Exp. 2023;11:57.37635181 10.1186/s40635-023-00541-3
29. Gomez A Froese L Bergmann TJG Sainbhi AS Vakitbilir N Islam A Non-invasive estimation of intracranial pressure-derived cerebrovascular reactivity using near-infrared spectroscopy sensor technology in acute neural injury: a time-series analysis Sensors 2024 24 499 10.3390/s24020499 38257592
Gomez A, Froese L, Bergmann TJG, Sainbhi AS, Vakitbilir N, Islam A, et al. Non-invasive estimation of intracranial pressure-derived cerebrovascular reactivity using near-infrared spectroscopy sensor technology in acute neural injury: a time-series analysis. Sensors. 2024;24:499.38257592 10.3390/s24020499
30. Gomez A Marquez I Froese L Bergmann T Sainbhi AS Vakitbilir N Near-infrared spectroscopy regional oxygen saturation based cerebrovascular reactivity assessments in chronic traumatic neural injury versus in health: a prospective cohort study Bioengineering 2024 11 310 10.3390/bioengineering11040310 38671733
Gomez A, Marquez I, Froese L, Bergmann T, Sainbhi AS, Vakitbilir N, et al. Near-infrared spectroscopy regional oxygen saturation based cerebrovascular reactivity assessments in chronic traumatic neural injury versus in health: a prospective cohort study. Bioengineering. 2024;11:310.38671733 10.3390/bioengineering11040310
31. Czosnyka M Guazzo E Whitehouse M Smielewski P Czosnyka Z Kirkpatrick P Significance of intracranial pressure waveform analysis after head injury Acta Neurochir (Wien) 1996 138 531 541 10.1007/BF01411173 8800328
Czosnyka M, Guazzo E, Whitehouse M, Smielewski P, Czosnyka Z, Kirkpatrick P, et al. Significance of intracranial pressure waveform analysis after head injury. Acta Neurochir (Wien). 1996;138:531–41 (discussion 541-542).8800328 10.1007/BF01411173
32. Jennett B MacMillan R Epidemiology of head injury Br Med J (Clin Res Ed) 1981 282 101 104 10.1136/bmj.282.6258.101 6779889
Jennett B, MacMillan R. Epidemiology of head injury. Br Med J (Clin Res Ed). 1981;282:101–4.6779889 10.1136/bmj.282.6258.101
33. Benjamini Y Hochberg Y Controlling the false discovery rate: a practical and powerful approach to multiple testing J Roy Stat Soc: Ser B (Methodol) 1995 57 289 300 10.1111/j.2517-6161.1995.tb02031.x
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc: Ser B (Methodol). 1995;57:289–300.10.1111/j.2517-6161.1995.tb02031.x
34. Jafari M, Ansari-Pour N. Why, When and How to Adjust Your p Values? CellJ [Internet]; 2019. 10.22074/cellj.2019.5992. Accessed 22 Apr 2022.
35. Glickman ME Rao SR Schultz MR False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies J Clin Epidemiol 2014 67 850 857 10.1016/j.jclinepi.2014.03.012 24831050
Glickman ME, Rao SR, Schultz MR. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J Clin Epidemiol. 2014;67:850–7.24831050 10.1016/j.jclinepi.2014.03.012
36. Donnelly J Czosnyka M Adams H Robba C Steiner LA Cardim D Individualizing thresholds of cerebral perfusion pressure using estimated limits of autoregulation Crit Care Med 2017 45 1464 1471 10.1097/CCM.0000000000002575 28816837
Donnelly J, Czosnyka M, Adams H, Robba C, Steiner LA, Cardim D, et al. Individualizing thresholds of cerebral perfusion pressure using estimated limits of autoregulation. Crit Care Med. 2017;45:1464–71.28816837 10.1097/CCM.0000000000002575
37. Thiara S Griesdale DE Henderson WR Sekhon MS Effect of cerebral perfusion pressure on acute respiratory distress syndrome Can J Neurol Sci 2018 45 313 319 10.1017/cjn.2017.292 29455690
Thiara S, Griesdale DE, Henderson WR, Sekhon MS. Effect of cerebral perfusion pressure on acute respiratory distress syndrome. Can J Neurol Sci. 2018;45:313–9.29455690 10.1017/cjn.2017.292
38. Stein KY Froese L Gomez A Sainbhi AS Vakitbilir N Ibrahim Y Time spent above optimal cerebral perfusion pressure is not associated with failure to improve in outcome in traumatic brain injury ICMx 2023 11 92 10.1186/s40635-023-00579-3 38095819
Stein KY, Froese L, Gomez A, Sainbhi AS, Vakitbilir N, Ibrahim Y, et al. Time spent above optimal cerebral perfusion pressure is not associated with failure to improve in outcome in traumatic brain injury. ICMx. 2023;11:92.38095819 10.1186/s40635-023-00579-3
39. Czosnyka M Miller C Participants in the international multidisciplinary consensus conference on multimodality monitoring. monitoring of cerebral autoregulation Neurocrit Care 2014 21 Suppl 2 S95 102 10.1007/s12028-014-0046-0 25208679
Czosnyka M, Miller C. Participants in the international multidisciplinary consensus conference on multimodality monitoring. monitoring of cerebral autoregulation. Neurocrit Care. 2014;21(Suppl 2):S95-102.25208679 10.1007/s12028-014-0046-0
40. Le Roux P Menon DK Citerio G Vespa P Bader MK Brophy GM Consensus summary statement of the international multidisciplinary consensus conference on multimodality monitoring in neurocritical care: a statement for healthcare professionals from the neurocritical care society and the European society of intensive care medicine Intensive Care Med 2014 40 1189 1209 10.1007/s00134-014-3369-6 25138226
Le Roux P, Menon DK, Citerio G, Vespa P, Bader MK, Brophy GM, et al. Consensus summary statement of the international multidisciplinary consensus conference on multimodality monitoring in neurocritical care: a statement for healthcare professionals from the neurocritical care society and the European society of intensive care medicine. Intensive Care Med. 2014;40:1189–209.25138226 10.1007/s00134-014-3369-6
41. Svedung Wettervik T Beqiri E Bögli SY Placek M Guilfoyle MR Helmy A Brain tissue oxygen monitoring in traumatic brain injury: part I-To what extent does PbtO2 reflect global cerebral physiology? Crit Care 2023 27 339 10.1186/s13054-023-04627-y 37653526
Svedung Wettervik T, Beqiri E, Bögli SY, Placek M, Guilfoyle MR, Helmy A, et al. Brain tissue oxygen monitoring in traumatic brain injury: part I-To what extent does PbtO2 reflect global cerebral physiology? Crit Care. 2023;27:339.37653526 10.1186/s13054-023-04627-y
42. Maloney-Wilensky E Le Roux P The physiology behind direct brain oxygen monitors and practical aspects of their use Childs Nerv Syst 2010 26 419 430 10.1007/s00381-009-1037-x 19937246
Maloney-Wilensky E, Le Roux P. The physiology behind direct brain oxygen monitors and practical aspects of their use. Childs Nerv Syst. 2010;26:419–30.19937246 10.1007/s00381-009-1037-x
43. Jöbsis FF Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters Science 1977 198 1264 1267 10.1126/science.929199 929199
Jöbsis FF. Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science. 1977;198:1264–7.929199 10.1126/science.929199
44. Jo Bsis-Vandervliet FF Discovery of the near-infrared window into the body and the early development of near-infrared spectroscopy J Biomed Opt 1999 4 392 396 10.1117/1.429952 23014610
Jo Bsis-Vandervliet FF. Discovery of the near-infrared window into the body and the early development of near-infrared spectroscopy. J Biomed Opt. 1999;4:392–6.23014610 10.1117/1.429952
45. Sen AN Gopinath SP Robertson CS Clinical application of near-infrared spectroscopy in patients with traumatic brain injury: a review of the progress of the field Neurophotonics 2016 3 031409 10.1117/1.NPh.3.3.031409 27226973
Sen AN, Gopinath SP, Robertson CS. Clinical application of near-infrared spectroscopy in patients with traumatic brain injury: a review of the progress of the field. Neurophotonics. 2016;3:031409.27226973 10.1117/1.NPh.3.3.031409
46. Güiza F Depreitere B Piper I Citerio G Chambers I Jones PA Visualizing the pressure and time burden of intracranial hypertension in adult and paediatric traumatic brain injury Intensive Care Med 2015 41 1067 1076 10.1007/s00134-015-3806-1 25894624
Güiza F, Depreitere B, Piper I, Citerio G, Chambers I, Jones PA, et al. Visualizing the pressure and time burden of intracranial hypertension in adult and paediatric traumatic brain injury. Intensive Care Med. 2015;41:1067–76.25894624 10.1007/s00134-015-3806-1
47. Svedung Wettervik T Beqiri E Hånell A Yu Bögli S Placek M Donnelly J Visualization of Cerebral pressure autoregulatory insults in traumatic brain injury Crit Care Med 2024 52 8 1228 1238 10.1097/CCM.0000000000006287 38587420
Svedung Wettervik T, Beqiri E, Hånell A, Yu Bögli S, Placek M, Donnelly J, et al. Visualization of Cerebral pressure autoregulatory insults in traumatic brain injury. Crit Care Med. 2024;52(8):1228–38.38587420 10.1097/CCM.0000000000006287
48. Zeiler FA Beqiri E Cabeleira M Hutchinson PJ Stocchetti N Menon DK Brain tissue oxygen and cerebrovascular reactivity in traumatic brain injury: a collaborative European neurotrauma effectiveness research in traumatic brain injury exploratory analysis of insult burden J Neurotrauma 2020 37 1854 1863 10.1089/neu.2020.7024 32253987
Zeiler FA, Beqiri E, Cabeleira M, Hutchinson PJ, Stocchetti N, Menon DK, et al. Brain tissue oxygen and cerebrovascular reactivity in traumatic brain injury: a collaborative European neurotrauma effectiveness research in traumatic brain injury exploratory analysis of insult burden. J Neurotrauma. 2020;37:1854–63.32253987 10.1089/neu.2020.7024
